FB Dec 2019 310.000 put

OPR - OPR Delayed Price. Currency in USD
147.81
0.00 (0.00%)
As of 12:01AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close147.81
Open147.20
Bid115.55
Ask116.30
Strike310.00
Expire Date2019-12-20
Day's Range147.05 - 147.81
Contract RangeN/A
Volume805
Open InterestN/A
  • Facebook unveils results of its conservative bias audit
    Yahoo Finance Video

    Facebook unveils results of its conservative bias audit

    Facebook's unveils results of its conservative bias audit. The roughly year-long conservative bias audit was conducted by former Sen. Jon Kyl and his team at the law firm Covington and Burling. It included interviews with approximately 133 conservative lawmakers and groups.

  • Financial Times

    FirstFT: Today’s top stories

    FT subscribers can click here to receive FirstFT every day by email. Scrutiny of Facebook’s Libra digital currency has spooked some of the project’s early backers , with at least three privately discussing ...

  • Financial Times

    Libra/Facebook: friends disunited

    The 27 founding fathers who plan to join Facebook in the creating digital currency Libra are right to have qualms. If Facebook and the rest of its partners want to set up a Swiss-based project there is little to stop them. EU antitrust regulators are now asking questions about the ways in which Libra would use personal information.

  • Financial Times

    Facebook’s Libra backers look to distance themselves from project

    digital currency has spooked some of the project's early backers, with at least three privately discussing how to distance themselves from the venture. The 28 members of the Libra Association, which include Visa, Mastercard, Uber, Spotify and the Facebook subsidiary Calibra, made a non-binding pledge to invest at least $10m in the project, which Facebook unveiled in June, with the aim of shaking up the global payments market. Two of the project’s founding backers told the FT they were concerned about the regulatory spotlight and were considering cutting ties.

  • Investopedia

    Banker's Remarks Roil Markets, but Buyers Respond

    Volatility shook traders out of Facebook, while investors might think that Boeing's bad times are behind it.

  • Seattle remains a battleground in the minimum wage debate
    American City Business Journals

    Seattle remains a battleground in the minimum wage debate

    More than four years after Seattle implemented an ordinance that raised the minimum wage for many local businesses to at least $15 per hour, the city continues to lead the national conversation. Seattle’s minimum wage ordinance went into effect in April 2015, and this year that law raised the minimum wage for employees of businesses with more than 500 employees to $16 per hour, while boosting minimum pay for employees of smaller businesses to $12 an hour, or $15 an hour if those employees don’t receive medical benefits or tips. Now the minimum wage momentum driven forward by Seattle and some of its top corporations appears to be surging nationally.

  • Reuters

    UPDATE 2-YouTube finds influence campaign tied to Hong Kong protests

    Alphabet Inc's Google announced on Thursday that its YouTube streaming video service disabled 210 channels appearing to engage in a coordinated influence operation around the Hong Kong protests, days after Twitter and Facebook said they dismantled a similar campaign originating in mainland China. "This discovery was consistent with recent observations and actions related to China announced by Facebook and Twitter," said Shane Huntley, one of Google's security leaders, in a blog post. Twitter Inc and Facebook Inc on Monday said that channels they had removed had engaged in a state-backed effort by China to undermine the protests in Hong Kong through posts calling participants dangerous and vile extremists.

  • Instagram Shopping Could Be Even Bigger Than Anticipated
    Motley Fool

    Instagram Shopping Could Be Even Bigger Than Anticipated

    Users love Instagram Checkout -- at least those that know about it.

  • California companies drive up competition, cost for Seattle tech talent
    American City Business Journals

    California companies drive up competition, cost for Seattle tech talent

    Seattle software engineers make an average $116,500 base salary a year, and California companies broadening their Seattle-area bases drive those figures up.

  • YouTube Closes 210 Accounts Tied to Hong Kong Influence Campaign
    Bloomberg

    YouTube Closes 210 Accounts Tied to Hong Kong Influence Campaign

    (Bloomberg) -- Google said it disabled 210 YouTube channels involved in “coordinate influence operations” around the Hong Kong protests, following similar measures earlier this week by social media companies Facebook Inc. and Twitter Inc.The Alphabet Inc. unit didn’t specify which channels were shut down in Thursday’s blog post announcing the decision. But the post said the company discovered accounts “consistent with recent observations and actions related to China” from Facebook and Twitter.The social media companies said earlier this week that they had removed hundreds of accounts linked to the Chinese government that were pushing messages meant to undermine the legitimacy of the protests in Hong Kong. Twitter also blocked advertising from state-controlled media. Facebook and Google have not made similar moves on advertising.YouTube, like Google search and other social media services, does not operate in China.To contact the reporter on this story: Mark Bergen in San Francisco at mbergen10@bloomberg.netTo contact the editors responsible for this story: Jillian Ward at jward56@bloomberg.net, Andrew Pollack, Robin AjelloFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • IBD's Investing Podcast: How To Make More Money In The Stock Market With Stock Charts
    Investor's Business Daily

    IBD's Investing Podcast: How To Make More Money In The Stock Market With Stock Charts

    Investing with IBD is a weekly podcast focused on helping investors learn how to make more money in the stock market by using stock charts to find top stocks.

  • Is Facebook Fueling the Hong Kong Protests?
    Market Realist

    Is Facebook Fueling the Hong Kong Protests?

    Facebook (FB) and Twitter (TWTR) are yet again the center of attention over claims of propagating disinformation, this time for the Hong Kong protests.

  • Facebook’s Libra Can’t Seem to Escape Challenges
    Market Realist

    Facebook’s Libra Can’t Seem to Escape Challenges

    It seems Libra may not have the smooth path to becoming a global currency Facebook had hoped for. Now European regulators are voicing concerns.

  • Facebook’s Housing Discrimination Troubles Persist
    Market Realist

    Facebook’s Housing Discrimination Troubles Persist

    Facebook is facing another housing discrimination lawsuit. A group of users have sued it to seek compensation for alleged discriminatory housing ads

  • Alphabet Stock Has Recession-Resistant Trump Cards
    InvestorPlace

    Alphabet Stock Has Recession-Resistant Trump Cards

    Although most investors consider the venerable Dow Jones as the benchmark index, in reality, folks should instead consider names like Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL), Facebook (NASDAQ:FB) and Amazon (NASDAQ:AMZN). After all, an investment toward Alphabet stock gives you wide-ranging exposure to the most relevant and lucrative sectors.Source: Valeriya Zankovych / Shutterstock.com Unfortunately, being relevant doesn't necessarily protect you from a broader market downturn. Since the U.S.-China trade war has ratcheted up several notches in intensity, equities have not offered much stability. That goes for the GOOGL stock price, along with the market values of the internet giant's peers.Of course, it's now very tempting to go discount shopping on big tech firms. For instance, Alphabet stock has shed more than 4% since gapping up on July 26. During this same period, rivals AMZN and FB have lost 6% and 8%, respectively.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis gamble might pay off for the speculator. But if your investing style leans more to the conservative end of the spectrum, there's nothing wrong with waiting. Yes, the GOOGL stock price below $1,200 is enticing. Based on the longer-term chart, shares really want to bust through the $1,300 level decisively. * 10 Marijuana Stocks to Ride High on the Farm Bill However, we could have a very ugly recession threat on our hands. Primarily, President Donald Trump may be losing control of the situation. Recently, he declared himself the "Chosen One" as he defended his aggressive stance on China. To me, this is the sound of panicking and bodes poorly for Alphabet stock in the interim.That's because history shows us - like the Smoot-Hawley Tariff Act - that wrong high-level choices have severe consequences. Therefore, you don't want to go crazy on GOOGL stock. The Risky, but Fundamentally Sound Case for Alphabet StockBut should you avoid GOOGL stock indefinitely?I'm going to be upfront. If you want both a defensive position and to stay in equities, I'd go for the boring companies: Procter & Gamble (NYSE:PG), Kimberly Clark (NYSE:KMB), and Home Depot (NYSE:HD). These are companies that have consistent demand. In my opinion, they're too boring to disrupt, giving them an Amazon moat.However, if you can handle some risk, I'd buy Alphabet stock on the next big dip. Why? Ultimately, the tech giant is a play on everything relevant.Principally, most analysts focus on the dominant presence that Alphabet levers in the U.S. digital-ad space. Together with Facebook, the fearsome duo takes home about 60% market share. Obviously, this is a compelling reason to consider Alphabet, especially if the GOOGL stock price tanks. Equity losses won't immediately translate to a loss in ad dominance.While competitors like Amazon are butting into the arena, GOOGL has a very sizable lead. And this synergizes well with Alphabet's supremacy in the search engine space.Let's zoom out to a wider angle. Even if we suffer a recession, we won't suddenly transition to a "Mad Max"-like society. Instead, people will do normal things, like look for a job. For such a purpose, Google (and Facebook) will see a lift in traffic, helping Alphabet stock move higher.Also, businesses desperate to gain traction will likely advertise through Google. Again, just because we're in a recession doesn't mean our behaviors will incur a paradigm shift. In this digitized economy, traditional advertising channels have become obsolete. Thus, if you want to do anything, you must do so digitally. It's unfair perhaps, but it's also a driving force for Alphabet stock. Multi-faceted Tech Business Supports GOOGL StockIf the digital-ad presence wasn't enough of a convincing reason, then investors should zoom out even wider.Whether or not you agree with the Trump administration's stance on China, the Asian power has compromised U.S. interests. In his world view, President Trump must hold China accountable for their actions.But underlining the events that led up to the trade war is China's desire to dominate world affairs. Their government even has a name for it: "Made in China 2025." And it's not just the second-biggest economy that's tired of American geopolitical hegemony. In recent years, Russia's actions harken back to the Soviet Union era.What does this have to do with Alphabet stock? The tech firm attained leadership in many of the categories for which our adversaries wish to dominate, such as artificial intelligence. Right now, U.S. government agencies are taking a close look at big tech's anti-competitive behaviors.But that prosecution will probably fade into the background if we have a recession, especially one related to an adversary. Instead, an economic downturn could translate to a rallying cry for GOOGL stock.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post Alphabet Stock Has Recession-Resistant Trump Cards appeared first on InvestorPlace.

  • Twitter Nears Critical Test at 2018 High
    Investopedia

    Twitter Nears Critical Test at 2018 High

    Twitter has rallied nearly 50% so far in 2019 and could lift into big tech leadership with a breakout above the 2018 high.

  • MiMedx Has Changed, But Its Critics Haven’t
    Bloomberg

    MiMedx Has Changed, But Its Critics Haven’t

    (Bloomberg Opinion) -- This is the second of two columns about MiMedx and the short-sellers. Read the first here.Most of the time, Eiad Asbahi, the 40-year-old founder of Prescience Point Capital Management, is a short-seller.According to its website, the firm, based in Baton Rouge, Louisiana, specializes “in extensive investigations of difficult-to-analyze public companies in order to uncover significant elements of the business that have been overlooked or ignored by others.” Such investigations usually lead to the discovery of problems that will cause the stock to fall once they become known.“But every now and then,” Asbahi says, “we find a company that is incredibly hated and where the shorts have it wrong.” SeaWorld Entertainment Inc., which has been hammered for its treatment of its whales and dolphins, was one such company. Two years ago, Asbahi bought the stock, believing that “the mispricing was extreme.” He was right. Since it bottomed out in November 2017, SeaWorld’s shares have more than tripled.On Jan. 8 of this year, Prescience Point released a report about its latest big investment idea: MiMedx Group Inc., a company that was under siege by Marc Cohodes and a handful of other short-sellers. After six months of research, Asbahi concluded that the thesis developed by the shorts — which had helped push the stock from $18 to $1.15 — was wrong.Contrary to what Cohodes et al were claiming, Prescience Point’s research suggested that MiMedx products were “legitimate and sustainable”; that it had positive cash flow; and that, while “channel stuffing” to improperly boost revenue at the end of the quarter had taken place, the company’s critics had “failed to produce any smoking guns to support their claims of massive fraud.”“In our view MDXG is one of the largest mispricings we have ever identified,” the report concluded. At the time it was issued, MiMedx stock was at $2.16. Prescience Point predicted that it would quadruple.When I spoke to Asbahi a few weeks ago — by which time the stock had topped $5 — he went further in his criticism of Cohodes and the other short-sellers. In his view, MiMedx’s stock had tanked in 2018 as much because of what the shorts had gotten wrong as what they had gotten right.“What we found,” Asbahi said, “is that they had some credible channel stuffing allegations” — and then they made a series of additional, less credible accusations. There was never any bribery or Medicare fraud, Asbahi said. And MiMedx’s products, often maligned by the shorts, were considered “best in class” by many doctors. “It is not a short activist campaign they’re running,” Asbahi concluded. “It is a smear campaign.”Cohodes’s initial allegations were serious enough that the MiMedx board hired a law firm to investigate. That investigation led to the discovery of the channel stuffing and the dismissal of several top MiMedx executives, including chief executive Parker Petit. But as I noted Monday, even after Petit and the others resigned, Cohodes kept MiMedx in his crosshairs, vowing to take down the company “if it’s the last thing I do.” Once Asbahi released his MiMedx report, Cohodes added Prescience Point to his list of targets.Within days of the report’s release, Cohodes was tweeting that it was “false & misleading” and that Prescience Point “will be ruined.” He has kept up a steady drumbeat of criticism ever since. Just a few weeks ago, he called Prescience Point a “pump-and-dump operation,” a charge he’s made several times before.This last allegation is ludicrous. Prescience Point is MiMedx’s largest shareholder, with 7.7% of the stock. In May, it launched a proxy fight that led to the company agreeing to add six new board members. Three of them were Prescience Point’s nominees.When I asked Cohodes what proof he had to back up the pump-and-dump charge, he replied (via email) that it was his understanding that Prescience Point had purchased the stock at between $6 and $10 a share — and was now “obviously attempting to generate positive interest to make back its investment.” He also said that Prescience Point had sold MiMedx stock after publishing “glowing information about the company.”In truth, Prescience Point bought the stock at an average price of about $2.60 a share, a fact that can be easily found in government disclosure documents. Although the firm sold some stock, it did so only to avoid triggering the company’s poison pill. Once the proxy fight ended — and the poison pill was a nonissue — Prescience Point bought more stock. “We set up a single-idea fund to invest in MiMedx with a two-year lockup,” Asbahi told me. “Does that sounds like a pump-and-dump scheme?”Today, MiMedx is a very different company from when Petit was running it. Of Petit’s 16 top executives, 13 are gone. Its new chief executive, Timothy Wright, has been a top level executive at a number of biotech and pharmaceutical companies, including Teva Pharmaceutical Industries Ltd, the big generics manufacturer.Among the new directors is Richard Barry, a respected health-care investor. He is so bullish about MiMedx’s prospects that he bought 3% the stock. All of this information is readily available. Yet Cohodes and his allies refuse to acknowledge that MiMedx has changed. Instead they are making the same allegations they’ve been making all along — except louder and more insistently.Why?Cohodes gave me two reasons. The first, he said, was that the company was still engaged in “criminal activity.” “Doctors have been bribed by MiMedx. And all the perps who carried out the fraud are still there doing it,” he told me.The second reason, he said, was that MiMedx’s products are deeply flawed. “This is a public health deal. This stuff is so bad, and they are taking advantage(1) of veterans. I have to speak out.”Let’s examine the bribery issue first. One doctor the shorts have targeted — including online — is Brandon Hawkins, a podiatrist in Bakersfield, California. He is a major buyer of MiMedx’s primary product, a wound graft made from placental tissue called EpiFix. Indeed, Hawkins told me he is probably the fourth or fifth biggest user of EpiFix in California. He has been paid by MiMedx to give occasional lectures, a common practice in medicine, which he discloses. His brother-in-law is a MiMedx salesman. And he lives quite well, something one can glean from the family’s Facebook page.The MiMedx critics have linked these facts to claim that Hawkins is on the take. But Hawkins says he uses EpiFix for a perfectly sensible reason: It works better than competing wound grafts. “Wounds that would normally heal in 12 to 20 weeks sometimes heal in four weeks with EpiFix,” he said. He added that there is a high incidence of diabetes in Bakersfield, and EpiFix has been an important tool in healing the foot ulcers that often develop in diabetics.Matthew Garoufalis,(2) a Chicago podiatrist, explained that diabetics are often “so immunocompromised” that their ulcers don’t heal. Studies show that some 20% of diabetics who develop foot ulcers will eventually have part or all of a leg amputated below the knee. But the placental-cell formula used in EpiFix “stimulates the wound healing cycle” even with ulcers that are not responding to other healing products, Garoufalis said. He also told me there are lots of good data affirming the efficacy of EpiFix. A 2016 study published in the International Wound Journal concluded that the technology used by EpiFix “is superior to standard care” in healing foot ulcers. After my first MiMedx column was published Monday, several of Cohodes’s short-selling allies took to Twitter, saying they had proof that MiMedx was guilty of bribing doctors. As Bloomberg News reported last year, three employees of a South Carolina Veterans Affairs hospital were indicted for accepting payments and other inducements from the company that resulted in “excessive use of MiMedx products.” One of the three was a doctor. The indictment, however, does not allege any wrongdoing by MiMedx. You see, MiMedx had contracts with the three VA employees — just as it has contracts with doctors all over the country. And MiMedx itself didn’t play a part in the conduct that got the VA employees into hot water. The employees were supposed to get the contracts approved by the hospital. But apparently that didn’t happen. The case wasn’t about bribery; it was about violating government rules. Within five months of the indictments, prosecutors had concluded that the case wasn’t worth going to trial over. The three employees agreed to “pretrial diversion,” meaning that if they paid the money back — about $3,500 in two cases, and about $20,000 in the third — the indictments would be dismissed. That happened in April.  What about Cohodes’s charge that MiMedx’s products are creating a public health hazard? This should also raise an eyebrow (or two). The product he is primarily criticizing is AmnioFix. It also uses placental tissue, but it’s processed in such a way that it can be injected. AmnioFix’s primary purpose is to relieve degenerative joint and tendon pain — pain that is currently difficult to treat. It’s a relatively new product, and many of those who are long MiMedx stock think it has blockbuster potential.Cohodes, however, says that AmnioFix has never been proved effective for anything, and that it hasn’t been approved by the Food and Drug Administration. “MiMedx was and is selling unapproved products to an unsuspecting and vulnerable public,” he said in an email. “People in pain often search for solutions in the unapproved drug world when they have run out of options. MiMedx has exploited that vulnerability and that is tragic.”Let me offer an alternate take. In December 2017, the FDA issued new guidelines for injectable tissue — and gave companies three years to come into compliance and get approved indications for their products. With a year and a half to go, MiMedx is in the middle of a Phase III trial for the use of AmnioFix to relieve plantar fasciitis, and a Phase II trial for osteoarthritis. MiMedx bulls think it will have the indications approved by the December 2020 deadline.Studies indicate that the technique MiMedx is pioneering with AmnioFix works: One showed that three months after an injection, 91 percent of patients felt significant pain relief. And the FDA is on record as saying that AmnioFix “has the potential to address unmet medical needs.” My exchanges with Cohodes left me with the distinct impression that he views AmnioFix as some kind of rogue drug, operating outside the FDA system. Based on everything I've learned, it’s not.Digging into Cohodes’s claims, I concluded that Asbahi is probably right: The short-seller and his allies are conducting a smear campaign intended to damage the company. I say this with a heavy heart. I’ve written in the past about companies Cohodes and his former partner David Rocker exposed, and I’m a big believer in the importance of short-sellers. Investors need to listen to skeptical voices as well as bullish ones. As a general rule, those who bet against companies are performing a service for all investors.But it’s also important that short-sellers tell the truth about what they find and have an open mind if a company, say, changes its tactics and its senior management. Stretching the facts to push a stock down is as bad as stretching them to push a stock up. And flogging a misguided narrative about products that could help millions of patients is just wrong. Campaigns like Cohodes’s against MiMedx give short-sellers a bad name.In an email, I asked Cohodes why he remained so obsessed with MiMedx. “You call it ‘obsessed,’ he replied, “but that’s the wrong word. I am committed to truth and always have been.”There was a time when I would have believed him. Not anymore.*****A postscript: On Monday afternoon, Bloomberg and I received a lengthy letter from Cohodes’s lawyer, David Shapiro, claiming that my first MiMedx column was “false and defamatory” and demanding a retraction. The letter reminded me of how this all started for Cohodes: with a presentation at a 2017 investment conference in which he denounced MiMedx and its then-CEO Petit for having sued three of the company’s critics. “Quit intimidating the shorts, the critics, the free speakers,” Cohodes said then. “It has to stop.”Apparently, Petit isn’t the only one willing to use intimidation tactics to quiet his critics.(1) Bloomberg’s standards regarding foul language prevent me from repeating his actual words.(2) I spoke to a third doctor, Raymond Otto of Boise, Idaho, who also praised EpiFix as a superior wound product. I should note that all three doctors have given lectures on MiMedx’s behalf. Garoufalis told me that the typical lecture fee is $1,500 or less.To contact the author of this story: Joe Nocera at jnocera3@bloomberg.netTo contact the editor responsible for this story: Stacey Shick at sshick@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Joe Nocera is a Bloomberg Opinion columnist covering business. He has written business columns for Esquire, GQ and the New York Times, and is the former editorial director of Fortune. His latest project is the Bloomberg-Wondery podcast "The Shrink Next Door."For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • 5 Pros (And 5 Cons) About Apple Stock
    InvestorPlace

    5 Pros (And 5 Cons) About Apple Stock

    When it comes to Apple (NASDAQ:AAPL) stock over the past several years, I've worn many hats -- including both the bear's hat and the bull's hat.Source: View Apart / Shutterstock.com Today, though, I choose not to wear either hat. The risk-reward profile on AAPL stock at current levels seems balanced. That is to say, there are some things to like about Apple stock. There also some things not to like about Apple stock. The things to like largely cancel out with things not to like, and net net, neither the bull nor the bear thesis on AAPL stock looks all that compelling to me at the current moment.To be sure, long term, Apple stock will go higher. But, the near term will probably be choppy, and that choppiness isn't something I'm too interested in buying into.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWithout further do, then, let's dive into five pros and five cons about AAPL stock, and see how the risks and rewards balance each other out here. 5 Pros About Apple StockIn no particular order, here are five pros about Apple stock right now.The Secular Growth Narrative Remains (Largely) Robust. Apple remains the Western world's favorite consumer technology company, with its products dominating the smartphone, laptop and smartwatch worlds. Sure, unit growth in those consumer hardware arenas is maxing out. But, Apple is successfully pivoting towards a software-driven growth narrative wherein Apple monetizes its extensive hardware install base with multiple subscription software services. Consumers are buying these services, and will continue to do so for the foreseeable future because they are addicted to the iOS ecosystem. In the long run then Apple's revenues and profits should grind higher, as should AAPL stock. * 10 Undervalued Stocks With Breakout Potential China Headwinds Are Easing. China has been a big problem for Apple because: 1) Apple's big growth engine is the China market, 2) China's economic growth is slowing, and 3) elevated trade war tensions between the U.S. and China create increased pricing risk for Apple's products. But, there are signs emerging that China's economy is starting to stabilize, and it appears elevated trade tensions are now cooling. Currency headwinds are also moderating. As such, Apple's China numbers should improve in the back-half of 2019.Big Services Catalysts Are on the Horizon. Apple has a few very big services catalysts on the horizon, including the launch of Apple TV+ and Apple Arcade in the last few months of 2019. If those services gain widespread traction quickly -- and they should, given that they have been hyped up and that Apple is pouring billions of dollars into them -- then investors will grow increasingly bullish on the long-term growth prospects of Apple's services business as we head into the close of 2019. That investor sentiment boost should provide a lift to AAPL stock. Click to EnlargeThe Chart Looks Pretty Good. In late 2018, Apple stock put in a multi-year bottom. Ever since, the stock has been a solid uptrend, forming a healthy multi-quarter support line which the stock has tested and held multiple times. So long as the stock keeps holding this support line, its technicals remain favorable for AAPL stock to stay in an uptrend.The Stock Is Cheap Relative to its Peer Group. AAPL stock presently trades at a forward price-to-earnings ratio of 16.6. That is about as cheap of a forward earnings multiple as you will find in big tech. Microsoft (NASDAQ:MSFT), Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL), Amazon (NASDAQ:AMZN) and Netflix (NASDAQ:NFLX) all trade over 20x forward earnings. 5 Cons About Apple StockAlso in no particular order, here are five cons about Apple stock right now.Some Cracks Are Starting to Form in the Secular Growth Narrative, Especially on the iPhone Side. The secular growth narrative of Apple pivoting into software growth as hardware growth has maxed out looks good. But, it's built on this idea that Apple will maintain a huge hardware install base. There are signs that Apple's hardware install base is already shrinking, though, as multiple reports (see here and here) point to the iPhone actually losing global market share over the past several quarters. If this trend accelerates -- admittedly, a big "if" -- then Apple's secular growth narrative could weaken dramatically.China Is a Wildcard With More Turbulence Coming. Apple's China headwinds are easing right now. But, the U.S.-China trade war is cyclical. It goes from "things are progressing," to more tariffs, to "things are progressing, again" -- and cycles through those phases back and forth. As such, there is another shoe waiting to drop here, and when it does drop, AAPL stock could get hit.Holiday iPhone Sales Will Likely Be Weak. Apple's 5G iPhones are set to launch next year. What about this year's new iPhone? It won't incorporate 5G, and that's big because other smartphone manufacturers are launching 5G phones in 2019. Thus, this holiday season, the smartphone landscape will include non-5G iPhones, and 5G "other smartphones." That isn't a favorable backdrop for healthy iPhone sales.Antitrust Risks Loom Large. I mostly subscribe to the idea that the legal fight against big tech amounts to just noise. Nonetheless, noise creates uncertainty, and investors tend to shy away from uncertainty. Thus, antitrust risks are an optical negative for AAPL stock.The Stock is Expensive Relative to its Historical Standard. While AAPL stock may be cheap next to its peers, it's also expensive relative to its historical standard. Specifically, Apple stock's five-year-average forward earnings multiple is about 14X -- roughly 25% below the current forward earnings multiple. The premium is being warranted by this idea that Apple's new software-driven growth narrative is higher margin and has more stability. Thus, if this software-driven growth narrative deteriorates at all, AAPL stock could be due for a sizable valuation pullback. Bottom Line on Apple StockThere are things to like about AAPL stock here -- good growth, easing headwinds, big catalysts, favorable technicals and a relatively cheap valuation. There are also things not to like about AAPL stock here -- cracks forming in the growth profile, wildcard trade and antitrust risks on the horizon, weak iPhone sales expected this holiday season and an above-average valuation.Putting all that together, it becomes fairly clear that the risk-reward profile on Apple stock is balanced. Until it tips one way or the other, I'm content on watching the Apple show from the sidelines.As of this writing, Luke Lango was long FB, GOOG, AMZN and NFLX. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post 5 Pros (And 5 Cons) About Apple Stock appeared first on InvestorPlace.

  • The Zacks Analyst Blog Highlights: JP Morgan, Mastercard, Facebook and IBM
    Zacks

    The Zacks Analyst Blog Highlights: JP Morgan, Mastercard, Facebook and IBM

    The Zacks Analyst Blog Highlights: JP Morgan, Mastercard, Facebook and IBM

  • Benzinga

    Microsoft The Latest To Be Criticized For Using Humans To Listen To User Audio

    Microsoft Corporation (NASDAQ: MSFT) is the latest tech company to be criticized for using humans to review audio captured through devices, raising more privacy concerns about in-home tech. Vice reported that contractors working for Microsoft were paid to listen to audio from Xbox users in the hopes of improving the gaming system’s voice command capabilities. The company responded in a statement to Vice that it has stopped listening to voice recordings captured by Xbox systems, though recordings are still made.

  • Has Amazon Outperformed SPY in the Past Five Days?
    Market Realist

    Has Amazon Outperformed SPY in the Past Five Days?

    Since August 14, Amazon (AMZN) has risen 3.4%. In the same period, the SPDR S&P; 500 ETF (SPY) has risen 3.0%. Let's see why AMZN outperformed.

  • How blockchain is being deployed for ESG
    Yahoo Finance Video

    How blockchain is being deployed for ESG

    A lot of people talk about blockchain and how it can revolutionize financial transactions and investing, but few people talk about its impact on social justice issues. Bond.One Chief Strategy Officer John Mizzi, joins Yahoo Finance’s Adam Shapiro, Dan Roberts, and Heidi Chung to discuss.